Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C.

J Clin Virol. 2014 Mar;59(3):148-55. doi: 10.1016/j.jcv.2013.12.011. Epub 2014 Jan 6.

PMID:
24462470
2.

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G.

Clin Gastroenterol Hepatol. 2013 Feb;11(2):193-5. doi: 10.1016/j.cgh.2012.10.045. Epub 2012 Nov 14.

PMID:
23159528
3.

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Lindsey KR, Gritz L, Sherry R, Abati A, Fetsch PA, Goldfeder LC, Gonzales MI, Zinnack KA, Rogers-Freezer L, Haworth L, Mavroukakis SA, White DE, Steinberg SM, Restifo NP, Panicali DL, Rosenberg SA, Topalian SL.

Clin Cancer Res. 2006 Apr 15;12(8):2526-37.

4.

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL.

J Virol. 2005 May;79(10):6554-9.

5.

Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.

Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.

Clin Cancer Res. 2005 Feb 15;11(4):1597-607.

6.

Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.

Peacock JW, Nordone SK, Jackson SS, Liao HX, Letvin NL, Yafal AG, Gritz L, Mazzara GP, Haynes BF, Staats HF.

J Virol. 2004 Dec;78(23):13163-72.

7.
8.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.

Clin Cancer Res. 2003 Aug 1;9(8):2973-80.

10.

Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.

Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J.

J Natl Cancer Inst. 2000 Aug 2;92(15):1228-39.

11.

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.

Clin Cancer Res. 2000 May;6(5):1632-8.

12.
13.

A triad of costimulatory molecules synergize to amplify T-cell activation.

Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J.

Cancer Res. 1999 Nov 15;59(22):5800-7.

14.

The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.

Kalus RM, Kantor JA, Gritz L, Gómez Yafal A, Mazzara GP, Schlom J, Hodge JW.

Vaccine. 1999 Feb 26;17(7-8):893-903.

PMID:
10067696
15.

Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity.

Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, Hijazi Y, Lee KH, Rosenberg SA, Marincola FM.

Ann Surg Oncol. 1998 Jan-Feb;5(1):64-76.

PMID:
9524710
16.

Inhibition of allergic encephalomyelitis in marmosets by vaccination with recombinant vaccinia virus encoding for myelin basic protein.

Genain CP, Gritz L, Joshi N, Panicali D, Davis RL, Whitaker JN, Letvin NL, Hauser SL.

J Neuroimmunol. 1997 Nov;79(2):119-28.

PMID:
9394784
17.

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.

Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA.

J Immunother. 1997 Jan;20(1):38-47.

PMID:
9101412
18.

A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.

Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, Gritz L, Panicali D, Kantor JA.

Int J Cancer. 1995 Oct 9;63(2):231-7.

PMID:
7591210
19.

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, Restifo NP.

J Immunol. 1995 May 1;154(9):4685-92.

20.

Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses.

Kent SJ, Stallard V, Corey L, Hu SL, Morton WR, Gritz L, Panicali DL, Greenberg PD.

AIDS Res Hum Retroviruses. 1994 May;10(5):551-60.

PMID:
7917517
Items per page

Supplemental Content

Write to the Help Desk